Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2] - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, leading to a class action notice for shareholders [3][4]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [3]. Group 2: Shareholder Actions - Shareholders who purchased shares during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment [3][4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025, and there is no cost or obligation to participate in the case [4]. Group 3: Legal Context - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions by companies that artificially inflated stock prices [5].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly making false and misleading statements regarding its drug candidate Pemvidutide, leading to investor losses when the trial results did not meet expectations [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased Altimmune's securities between August 10, 2023, and June 25, 2025, are encouraged to participate in the lawsuit before the deadline of October 6, 2025 [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Company Performance and Misleading Statements - Altimmune promoted the performance of Pemvidutide prior to the results of its IMPACT Phase 2B MASH trial, which ultimately failed to achieve statistically significant results in its primary endpoint [4]. - The company downplayed the trial's failure, suggesting it anticipated better outcomes from a subsequent Phase 3 trial, which contributed to the misleading nature of its public statements [4]. - As a result of these misleading statements, investors experienced financial damages when the truth about the company's performance was revealed [4].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [2]. Group 1: Company Overview - Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, Altimmune's management made positive statements about the expected results of the MASH trial [2]. - On June 26, 2025, Altimmune announced that it failed to achieve statistical significance in the trial due to a higher-than-expected placebo response, resulting in a stock price drop from $7.71 to $3.61, a decline of over 53% in one day [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must submit their papers by October 6, 2025, and can choose to remain absent class members if they do not wish to participate [3].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which failed to meet expectations [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, with a deadline of October 6, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations and Trial Results - The complaint alleges that Altimmune's executives made overly positive statements while concealing material adverse facts about the trial results [3]. - On June 26, 2025, Altimmune announced that one of the primary endpoints in the trial did not achieve statistical significance, attributed to a higher-than-expected placebo response [4]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant single-day decline of 53.2% [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, to discuss their legal rights [1] - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [4][8] - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8] Group 2: Trial Results and Stock Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]

Core Viewpoint - A securities class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [1][2][4]. Group 1: Allegations and Trial Results - The lawsuit claims that Altimmune executives provided overly positive statements while concealing adverse facts about the trial results [2]. - The press release announcing the trial results was titled positively, despite one of the primary endpoints not achieving statistical significance [2][3]. - The trial showed a positive trend in fibrosis improvement, but the statistical significance was not met due to a higher-than-expected placebo response [3]. Group 2: Market Reaction - Following the announcement of the trial results, Altimmune's stock price fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4]. Group 3: Legal Proceedings - Investors who purchased shares of Altimmune during the class period are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline on October 6, 2025 [5].

Core Viewpoint - A class action lawsuit has been initiated against Altimmune, Inc. following disappointing results from its Phase 2b MASH trial of Pemvidutide, leading to a significant drop in the company's stock price [1][3][4]. Company Overview - Altimmune, Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, including MASH [3]. Legal Proceedings - The lawsuit, Dave Collier v. Altimmune, Inc., was filed in the United States District Court for the District of Maryland, targeting all individuals who purchased Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - Investors have until October 6, 2025, to request to be appointed as lead plaintiff in the case [4]. Trial Results - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The company had previously set inflated expectations for the trial results, which were not met due to a higher-than-expected placebo response [3]. Stock Performance - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4].

Core Viewpoint - Investors are expected to focus on Altimmune's progress with its lead pipeline candidate, pemvidutide, during the second-quarter 2025 results announcement, as the company currently lacks a marketed drug and is projected to report a loss of 32 cents per share [1][10]. Group 1: Pipeline Candidate and Clinical Trials - Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist being developed for obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease (ALD), and alcohol use disorder (AUD) [2]. - The phase IIb IMPACT study showed that at 24 weeks, 59.1% and 52.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg achieved MASH resolution without worsening fibrosis, compared to 19.1% with placebo [3]. - Fibrosis improvement without worsening MASH was observed in 31.8% and 34.5% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% with placebo, although these differences were not statistically significant [4]. Group 2: Weight Loss and Safety Profile - Participants receiving pemvidutide experienced an average weight loss of 5% with the 1.2 mg dose and 6.2% with the 1.8 mg dose, compared to 1% in the placebo group at 24 weeks, indicating a favorable weight loss profile [5]. - Treatment with pemvidutide was generally safe and well-tolerated, which is a positive aspect for its future development [5]. Group 3: Market Performance and Future Expectations - Year to date, Altimmune's shares have declined by 43%, contrasting with a 7.2% increase in the industry [5]. - The company has initiated two separate phase II studies for pemvidutide targeting AUD and ALD, with further updates expected during the upcoming earnings call [6][7]. - Operating expenses are anticipated to have decreased in the upcoming quarter due to the timing of clinical study costs [7]. Group 4: Earnings Surprise History - Altimmune has a mixed earnings surprise history, having beaten estimates in three of the last four quarters, with an average surprise of 9.21% [8]. - In the last reported quarter, the company posted an earnings surprise of 25.71% [8].